AEAhmed Abdullah Abo Elnaga

Ahmed Abdullah Abo Elnaga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmed Abdullah Abo Elnaga has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis

    by Ahmed Farid Gadelmawla, Ahmed A. Abo Elnaga, Abdullah Faisal Albukhari, Raseel B. Almutairi, Basmah Alamri, Sami Mohammed Alhuways, Fatemah Althaher, Flwah Aloufi, Abdullah Mohammed A. Alotaibi, Abdullah Alali, et al.

    1. Sarcomas are rare and heterogeneous mesenchymal malignancies, constituting approximately 1% of adult cancers [1] and an even larger proportion of pediatric cancers [2], with a vast array of hist...

  • Open Access

    Safety and efficacy of tirofiban as an adjunct to endovascular thrombectomy in large vessel occlusion stroke: A systematic review and meta-analysis with GRADE assessment

    by Mostafa Hossam El Din Moawad, Dina Essam Abo-Elnour, Yasmine M. Osman, Mohamed Hendawy, Muhammad Daoud Tariq, Ahmed Hassan A. Rady, Anfel Rahai, Ahmed Abdullah Abo Elnaga, Ibrahim Serag, Ibraheem M. Alkhawaldeh, et al.

  • Alteplase versus tenecteplase in acute ischemic stroke with large vessel occlusion: a systematic review and meta-analysis

    by El Din Moawad, Mostafa Hossam, Ibrahim Serag, Abo Elnaga, Ahmed A., Dina Essam Abo-Elnour, Hamza A. Abdul-Hafez, Mohamed Ahmed Hammad, Lobna Ahmed Mohamed, Rawan Kamal Mohamed, et al.

    Background Intravenous thrombolysis remains a cornerstone in acute ischemic stroke (AIS) management, particularly in large vessel occlusion (LVO). While alteplase has long been the standard thrombolytic agent, tenecteplase has emerged as a promising alternative due to its pharmacokinetic advantages. This systematic review and meta-analysis aim to compare the efficacy and safety of tenecteplase versus alteplase in AIS patients with LVO. Methods A systematic search was conducted across PubMed, Scopus, Web of Science, Cochrane Library, and Embase until February 2025. Studies comparing tenecteplase and alteplase in AIS patients with LVO were included. The primary outcomes were functional independence at 3 months (modified Rankin Scale [mRS] 0–1 and 0–2), mortality, and symptomatic intracranial hemorrhage (sICH). Secondary outcomes included any bleeding, adverse events, and overall complications. Pooled estimates were calculated using risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI). Results A total of 14 studies (N = 9641 patients) were included, comprising 5898 patients receiving alteplase and 3743 receiving tenecteplase. No significant differences were observed in 3-month functional outcomes: mRS 0–1 (RR = 0.92, 95% CI: 0.78 to 1.1, P = 0.38) and mRS 0–2 (RR = 0.95, 95% CI: 0.83 to 1.08, P = 0.44). Mortality rates were comparable between groups (OR = 1.07, 95% CI: 0.88–1.30). No significant differences were found in intracranial hemorrhage (ICH) (OR = 1.25, 95% CI: 0.96–1.62), sICH (OR = 1.1, 95% CI: 0.91–1.33), or any bleeding (OR = 1.19, 95% CI: 0.9–1.57). The pooled OR for adverse events was 0.79 (95% CI: 0.53 to 1.17), indicating a comparable safety profile. Conclusion This meta-analysis supports the non-inferiority of tenecteplase compared to alteplase in LVO-associated AIS regarding efficacy and safety. While tenecteplase offers practical advantages, including single-bolus administration and potentially lower costs, further large-scale randomized controlled trials are needed to confirm these findings and optimize thrombolytic selection in stroke care.